Literature DB >> 25732171

Does degree of androgen suppression matter in hormone-sensitive prostate cancer?

Daniel L Suzman1, Emmanuel S Antonarakis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25732171      PMCID： PMC4886659          DOI： 10.1200/JCO.2014.60.1419

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

1.  Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.

Authors:  Nathan Lawrentschuk; Kimberly Fernandes; David Bell; Jack Barkin; Neil Fleshner
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

2.  SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

Authors:  Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

3.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

4.  Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making.

Authors:  M G Oefelein; A Feng; M J Scolieri; D Ricchiutti; M I Resnick
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

Review 5.  Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.

Authors:  David J Samson; Jerome Seidenfeld; Brian Schmitt; Vic Hasselblad; Peter C Albertsen; Charles L Bennett; Timothy J Wilt; Naomi Aronson
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

6.  Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.

Authors:  Robert W Ross; William K Oh; Wanling Xie; Mark Pomerantz; Mari Nakabayashi; Oliver Sartor; Mary-Ellen Taplin; Meredith M Regan; Philip W Kantoff; Matthew Freedman
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

7.  Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.

Authors:  Charles J Ryan; Arturo Molina; Jinhui Li; Thian Kheoh; Eric J Small; Christopher M Haqq; Russell P Grant; Johann S de Bono; Howard I Scher
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Intermittent versus continuous androgen deprivation in prostate cancer.

Authors:  Maha Hussain; Catherine M Tangen; Donna L Berry; Celestia S Higano; E David Crawford; Glenn Liu; George Wilding; Stephen Prescott; Subramanian Kanaga Sundaram; Eric Jay Small; Nancy Ann Dawson; Bryan J Donnelly; Peter M Venner; Ulka N Vaishampayan; Paul F Schellhammer; David I Quinn; Derek Raghavan; Benjamin Ely; Carol M Moinpour; Nicholas J Vogelzang; Ian M Thompson
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

9.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

10.  Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.

Authors:  Laurence Klotz; Chris O'Callaghan; Keyue Ding; Paul Toren; David Dearnaley; Celestia S Higano; Eric Horwitz; Shawn Malone; Larry Goldenberg; Mary Gospodarowicz; Juanita M Crook
Journal:  J Clin Oncol       Date:  2015-03-02       Impact factor: 44.544
View more
  2 in total

Review 1.  Mechanisms of Therapeutic Resistance in Prostate Cancer.

Authors:  Mary Nakazawa; Channing Paller; Natasha Kyprianou
Journal:  Curr Oncol Rep       Date:  2017-02       Impact factor: 5.075

Review 2.  Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Authors:  E David Crawford; Neal D Shore; Daniel P Petrylak; Celestia S Higano; Charles J Ryan
Journal:  Ther Adv Med Oncol       Date:  2017-03-22       Impact factor: 8.168
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.